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The degradation of human low density lipoprotein (LDL) was analyzed in fasted rats treated for 3 days 
with either 4-aminopyrazolo-(3,4-d)pyrimidine (4APP) or saline. Treatment with 4APP caused an 80% de- 
crease in serum cholesterol concentration. The mono-exponential serum decay of a tracer amount of labelled 
LDL was changed neither by 4APP treatment, nor by the simultaneous injection of a bolus of unlabelled 
LDL. The sites of degradation of human LDL were determined using the nondegradable labelling compound 
0-(4-diazo-3-[1251]iodobenzoyl)sucrose (DiZSIBS). The sites of degradation and the rate of degradation of 
Diz51BS labelled LDL were also not affected by 4APP treatment or by injection of a bolus of unlabelled 
LDL. It is concluded that human LDL is catabolised in the rat by way of a nonsaturable, low-affinity 
mechanism. 
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1. INTRODUCTION 
The catabolic pathway of serum LDL has been 
studied extensively by the group of Brown and 
Goldstein (review [1,2]). It was shown that LDL 
catabolism is initiated by the binding of LDL to a 
saturable, high-affinity receptor (LDL- or B/E- 
receptor) on the cell surface. There is considerable 
evidence that the number of LDL receptors is 
regulated by the cellular need for cholesterol. In 
the absence of LDL receptors (homozygous 
familial hypercholesterolemia) LDL is degraded by 
a nonsaturable, low-affinity mechanism. 
The rat has been used extensively as an ex- 
perimental model for the study of lipoprotein 
metabolism in vivo. Because the plasma LDL con- 
centration in the rat is very low, human LDL was 
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used instead in most of these metabolic studies. 
However, several in vitro binding studies have pro- 
vided evidence that human and rat LDL bind with 
different binding characteristics to LDL receptors 
in rat tissues [3,4]. Moreover, it has repeatedly 
been observed that the serum decays of human and 
rat LDL in the rat are not identical [5,6]. These 
studies indicate that human and rat LDL are not 
metabolised by the same catabolic pathway in the 
rat. Here, we evaluated the mechanisms of human 
LDL catabolism in the rat. 
2. MATERIALS AND METHODS 
Male retired breeders of the Wistar strain, 
weighing 300-400 g, were used in all experiments. 
One ml of 4APP (Aldrich-Europe, Beerse, 
Belgium), dissolved in saline, was administered in- 
traperitoneally without anaesthesia t a concentra- 
tion of 20 mg/kg for 3 consecutive days. Control 
animals were injected with saline. All animals were 
given free access to water, but food was withheld. 
Body weights of the rats treated with 4APP 
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decreased from 356 + 22 g to 3 16 f 19 g (n = 27) 
and of control rats from 347 + 23 g to 312 + 23 g 
(n = 9). 
Human LDL, isolated by sequential ultracen- 
trifugation, was iodinated with 13iI using the ICI 
method and with D”‘IBS, as described [7]. The 
radiolabelled LDLs were mixed and ‘screened’ in 
vivo, as described [7], except hat it was performed 
in rats treated with 4APP. One min prior to the in- 
travenous injection of labelled LDL under light 
ether anaesthesia, 2 ml of either unlabelled LDL 
(containing about 12.5 mg LDL cholesterol) or 
Krebs-Henseleit buffer [8] were injected into a 
femoral vein. The mixture of 1311-LDL and 
D’251BS-LDL was injected into the contralateral 
vein in a volume of 1 ml. Three min after the injec- 
tion of labelled LDL a blood sample was obtained 
from the orbital plexus behind the eye. The 
radioactivity in this sample was taken to be the in- 
itial serum radioactivity for the calculation of the 
serum decay. 0.25, 1 and 4 h after injection of 
labelled LDL the animals were anaesthetised with 
ether and bled from the abdominal aorta. The 
blood was allowed to clot at room temperature and 
serum was isolated by low speed centrifugation. A 
number of tissues (heart, lungs, liver, spleen, 
kidneys, jejunum, adipose tissue, muscle, hide, 
adrenals and testes) were excised, weighed and 
counted for radioactivity. The DIBS-dependent ac- 
cumulation in each tissue was calculated as in [7]. 
Na12? (350-600 mCi/ml) and Na1311 (40 mCi/ 
ml), both carrier-free, were obtained from Amers- 
ham International, Amersham, England. Choles- 
terol was measured by an enzymatic method as 
described [9]. All data presented are means + SD 
with the number of experiments in parentheses. 
3. RESULTS AND DISCUSSION 
When iodinated human LDL was injected in- 
travenously in tracer amounts in the rats used in 
this study, a monoexponential serum decay was 
observed during the 4 h experiment with a tl/2 of 
9.4 + 0.2 h (n = 3), measured by extrapolation un- 
til 50% of the injected dose was removed from the 
serum compartment. This value is in excellent 
agreement with data obtained from long-term ex- 
periments in male rats fasted overnight. In these 
animals we also measured monoexponential serum 
decays of human “‘1-LDL (tm 10.0 f 0.7 h; n = 
3). The serum radioactivity was measured at 1, 4, 
8, 20 and 28 h after injection of ‘251-LDL. When 
a bolus injection of unlabelled human LDL was 
given intravenously, 1 min prior to the injection of 
labelled LDL, the serum cholesterol concentration 
was raised approx. 3-fold and remained elevated 
for at least 4 h (fig.1). However, the serum decay 
of labelled human LDL was essentially unchanged 
with a tl/z of 9.7 +- 0.4 h (n = 3). This indicates 
that the catabolic pathway of human LDL in the 
rat is not saturable, not even at this, for the rat, ex- 
tremely high serum LDL concentration. 
Kovanen et al. [IO] showed that the LDL recep- 
tor for human LDL in liver membranes isolated 
from normal rats is virtually nondetectable. 
Therefore we thought of ways to increase the LDL 
receptor level and LDL degradation in the rat. 
Cells in tissue culture are able to increase the 
number of LDL receptors, and therefore the 
capacity to degrade LDL, in response to incuba- 
tion in lipoprotein-deficient medium [ 1,2]. In vivo 
experiments showed that 4APP dramatically 
reduces the serum cholesterol concentration in the 
rat [I 1,121, probably by inhibition of lipoprotein 
synthesis and secretion from the liver. It was also 
shown that 4APP treatment increases LDL bind- 
ing in the adrenal glands of the mouse [13]. These 
studies suggested that 4APP treatment could in- 
crease the rate of catabolism of LDL in vivo. 
However, in this study it was found that the serum 
decay of labelled human LDL from rat serum was 
not influenced at all by 4APP treatment. The 
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Fig. 1. Serum cholesterol concentrations. The serum 
cholesterol concentrations of control rats injected buffer 
(0) or unlabelled human LDL (0), and of 4APP-treated 
rats injected buffer ( n ) or unlabelled human LDL ( q ) 
were measured by an enzymatic method [9]. Results are 
means k SD for 3 experiments. 
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serum decay of iodinated human LDL in 4APP- 
treated animals had a ti/z of 9.3 f 0.2 h (n = 3), 
indicating that the catabolic pathway for human 
LDL in the rat cannot be upregulated in vivo by 
4APP treatment. When unlabelled LDL was in- 
jected into 4APP treated rats just prior to the in- 
jection of iodinated LDL, the plasma cholesterol 
concentration was raised to 100 mg/dl (fig.1). 
However, the serum decay of labelled human LDL 
was not affected and the t1/2 was 9.5 f 0.3 h (n = 
3), indicating again that the catabolic pathway of 
human LDL in the rat is not saturable. Also the 
disappearance rate of injected unlabelled human 
LDL-cholesterol is essentially unchanged by 4APP 
treatment (see fig. 1). 
The sites of catabolism of the protein moiety of 
human LDL were analysed with the nondegradable 
labelling compound DIBS. In agreement with [7], 
we observed no difference between the serum 
decay of conventionally iodinated LDL and DIBS- 
labelled LDL (not shown), indicating that the 
DIBS label does not affect the in vivo turnover of 
LDL. Recently we observed that DIBS-labelled 
human LDL is catabolised predominantly in the 
rat liver [7], as shown previously with sucrose- 
labelled human LDL [14,17]. Here, it was found 
that under all conditions (control rats, control rats 
+ unlabelled human LDL, 4APP-treated rats, 
4APP-treated rats + unlabelled LDL) the liver re- 
mained the most prominent site of catabolism of 
human LDL. The DIBS-dependent accumulation 
of radioactivity, an index of the rate of catabolism 
of LDL, was calculated for each tissue as described 
in [7]. There were no statistically significant dif- 
ferences in the DIBS-dependent accumulation in 
the liver after injection of radiolabelled LDL under 
any of the conditions mentioned above (fig.2). In 
agreement with the data obtained from the serum 
decays of radioactive human LDL, there is 
therefore no evidence that the rate of catabolism of 
labelled LDL in the liver is influenced by the serum 
LDL concentration or by 4APP treatment. 
Besides the liver the only tissue that showed any 
DIBS-dependent accumulation of radioactivity 
was the spleen. 4 h after injection of labelled LDL 
this tissue only accumulated less than 0.5% of the 
injected dose, and this percentage was not changed 
by a bolus injection of unlabelled LDL or 4APP 
treatment. 
Evidence suggesting that the adrenal gland is, 
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Fig.2. DIBS-dependent accumulation of LDL-derived 
radioactivity in the liver. The DIBS-dependent 
accumulation of LDL radioactivity in the liver of control 
rats injected buffer (0) or unlabelled human LDL (0), 
and of 4APP-treated rats injected buffer (0) or 
unlabelled LDL (0) was calculated as described in [7] 
by subtracting the percentage of the injected dose of the 
13’I-labelled LDL from that of the injected dose of the 
D’2sIBS-labelled LDL present in the liver at the 
indicated times. Results are expressed as means k SD for 
3 experiments. 
per g tissue, by far the most active organ for LDL 
binding has been presented [ 151. However, in 
agreement with [7], we observed no significant 
DIBS-dependent accumulation of LDL-derived 
radioactivity during the 4 h experiment in the 
adrenal glands of control rats and of control rats 
injected with a bolus of unlabelled LDL. 4APP 
treatment causes an almost 2-fold increase in the 
wet weight of the adrenal glands (not shown). It is 
not clear why the adrenal gland increases in size in 
response to 4APP treatment, but it can be 
speculated that it is a compensatory reaction of the 
tissue to the hypocholesterolemia, because the 
adrenal glands of rats treated with 17~~ 
ethinylestradiol showed a similar increase in wet 
weight. As shown in fig.3, the LDL-derived 
radioactivity in the adrenal glands of animals 
treated with 4APP increases approx. 5-fold, if 
compared with the radioactivity in the adrenal 
glands of control animals. The adrenal gland was 
the only tissue in which this increase was observed. 
However, the radioactivity associated with the 
adrenal glands could not be diminished by a bolus 
injection of unlabelled LDL. The increased 
association of labelled LDL with the adrenal 
glands of 4APP-treated animals cannot be fully ex- 
plained by the increased adrenal weight, but the in- 
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Fig.3. Accumulation of LDL-derived radioactivity in the 
adrenal glands. Accumulation of intravenously injected 
DIZSIBS-labelled LDL in the adrenal glands of rats 
injected with buffer (0) or unlabelled human LDL (0), 
or of 4APP treated rats injected buffer (0) or 
unlabelled LDL (0) is expressed as percent of the 
injected dose. Values are means + SD for 3 experiments. 
ability to decrease the radioactivity with excess 
unlabelled LDL indicates that this LDL binding is 
not saturable. It is unlikely that the increased LDL 
binding is related to LDL degradation, because 
DIBS-dependent accumulation could not be 
detected in the adrenal glands of 4APP-treated 
animals. 
Our data indicate that the catabolic pathway of 
human LDL in the rat is not saturable by the injec- 
tion of a high dose of unlabelled LDL, a conclu- 
sion reached before by others [16], using a dif- 
ferent methodology. Moreover, the present data 
show that the catabolic pathway of human LDL in 
the rat cannot be upregulated by a prolonged 
reduction of the plasma cholesterol concentration 
caused by 4APP treatment. It is therefore likely 
that human LDL is not catabolised in the rat by 
way of a saturable, high-affinity mechanism, but 
by a nonsaturable, low-affinity process. This con- 
clusion seems to be at variance with the results of 
earlier studies which showed that methylated 
human LDL is removed slower from rat serum 
than native human LDL [6,17,18]. However, using 
the same chemical modification, Koelz et al. [16] 
could not find any evidence in favor of a receptor- 
mediated clearance of human LDL by the rat liver 
or adrenal glands. In addition Chao et al. [19] 
reported that the removal of cyclohexanedione- 
modified ‘251-LDL from the blood of control rats 
is not very different from that of native 1251-LDL. 
It is evident that the results obtained with 
chemically modified human LDL in the rat are not 
consistent. These experiments are based on the 
assumption that chemically modified LDL and 
native LDL interact in the same way with LDL 
receptors in the rat in vivo as they do with LDL 
receptors in vitro. It is also assumed that chemical- 
ly modified human LDL is not recognized as 
foreign material and therefore rapidly removed 
from the circulation. In this respect it could be of 
importance that the f1/2 of about 10 h for native 
human ‘251-LDL observed in this study is higher 
than the fr/2 of l-3 h for the initial rapid phase 
observed by others [6,14]. In this study a different 
approach was used to study the mechanism of 
human LDL catabolism in the rat, which is based 
on the notion that a receptor-mediated process is 
characterised by the presence of a competition of 
a large bolus of unlabelled LDL with a tracer 
amount of labelled LDL. Our study indicates that 
the in vivo catabolism of human LDL in the rat is 
not mediated by the ‘classical’ LDL receptor 
pathway as described by Brown and Goldstein 
[1,2]. It is thought that the information for the 
LDL receptor protein, although present on the rat 
genome, hardly results in functioning receptors for 
human LDL at the liver cell surface [10,20]. The 
LDL receptor is induced only after treatment of 
rats with very high doses of 17cu-ethinylestradiol. 
This results in a 3-lo-fold increase in the binding 
of human LDL to liver membranes and a 12-fold 
increase in the hepatic uptake of intravenously ad- 
ministered human LDL [lo]. Human LDL has 
been used in most experiments dealing with LDL 
metabolism in the rat. The results of the present 
study underline the importance of the source of 
lipoproteins (homologous vs heterologous) in 
metabolic studies. 
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